Articles tagged with Cancer Cells
A new grant aims to decipher how diverse breast cancer tumors influence cancer cells' ability to resist treatment. By studying this phenomenon, researchers hope to uncover novel targets for more effective therapies.
Researchers aim to treat pancreatic ductal adenocarcinoma by targeting amino acid transporter SLC6A14 and compensatory nutrient scavenging mechanisms autophagy and macropinocytosis. Using alpha-methyl-L-tryptophan and hydroxychlorquine, the study seeks to improve therapeutic outcomes in patients with pancreatic cancer.
Researchers developed a targeted chemotherapy that selectively disrupts DNA replication and repair in cancer cells, leaving healthy cells unaffected. The investigational small molecule AOH1996 has been effective in treating various types of solid tumors in preclinical research.
Researchers at UMass Amherst have discovered a potential new medical therapy for Lyme disease using lactate dehydrogenase inhibitors typically used to combat cancer. The study found that these inhibitors substantially impacted Borrelia burgdorferi growth, making them promising candidates against Lyme infections.
Scientists at Max Delbrück Center discovered two lead compounds that inhibit activation of IKK/NF-κB pathway only when triggered by DNA double-strand breaks. These substances make cancer cells more sensitive to chemotherapy, potentially increasing the success rate of genotoxic cancer therapies.
A breakthrough treatment targeting bone marrow cancer cells destroyed 90% of multiple myeloma cells in laboratory tests and 60% in human tissue samples. Researchers developed lipid-based nanoparticles containing RNA molecules that silence the CKAP5 gene, inhibiting cancer cell division.
Researchers have identified KIAA0930 as a key factor causing muscle atrophy in cancer cells, which could lead to the development of new anti-cachexia therapies. The study found that KIAA0930 knockdown cells showed increased muscle mass and weight compared to control cells.
A new study reveals that cancer cells reprogram normal mesothelial cells into cancer-associated mesothelial cells through the AMH axis, promoting tumor growth and immune evasion. Disrupting this signal slows tumor growth and helps the immune system overcome some of its defenses.
Researchers have identified a new therapeutic target for glioblastoma brain cancer by finding that the 'don't eat me!' signal sent by cancer cells can be blocked using antibodies. This breakthrough suggests that existing immunotherapies may be effective against glioblastomas if the receivers on macrophages are switched off.
A new study by researchers at Dartmouth Cancer Center shows that a combination of estrogen and PARP inhibitors can effectively treat advanced ER+ breast cancer by damaging cancer cells and preventing DNA repair. The treatment strategy has been shown to be effective regardless of BRCA1 or BRCA2 genetic mutations.
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
Researchers at Nagoya University have discovered three new biomarkers for high-grade serous ovarian carcinoma using membrane proteins and polyketone-coated nanowires. The study reveals that small extracellular vesicles containing these proteins can be used to detect ovarian cancer, potentially leading to personalized medicine.
Researchers have found that PD-L1 triggers signaling that intrinsically alters cancer cell phenotype, impacting immune milieu. The study's findings suggest a new approach to treating patients with limited response to immunotherapy.
Researchers have developed a technology to capture and release cell-free DNA from urine using nanowire surfaces, successfully detecting IDH1 mutation in glioma patients. This method opens possibilities for the detection of other tumor mutations and could revolutionize cancer diagnosis.
Researchers at Tel Aviv University have developed a novel approach to fight cancer by inducing cancer cells to produce a toxic protein using mRNA molecules. The treatment was successful in eliminating 44-60% of cancer cells in animal models, with no damage to healthy cells.
Researchers at Aarhus University have discovered a new method to activate the complement system using bispecific single-domain antibodies, termed BiCEs. These molecules can specifically target cancer cells and activate the complement system, leading to the killing of targeted cancer cells.
Researchers used 3-D models to show that gene activity differs based on a cell's location within a tumor, influencing its role in cancer biology. The study could lead to more precise therapies by targeting specific areas of tumors.
A preclinical study has uncovered the role of Y chromosome gene KDM5D in regulating anti-tumor immune responses and promoting metastasis in male patients with KRAS-mutated colorectal cancer. The study reveals that mutant KRAS drives upregulation of KDM5D, leading to reduced cell adhesion and immune recognition by the immune system.
Researchers found that loss of the Y chromosome in bladder cancer cells allows them to evade the immune system, leading to aggressive growth. However, this loss also renders the disease more responsive to a standard treatment called immune checkpoint inhibitors.
Researchers found that leukemia cells use messenger particles to navigate and release molecular cargo at distant sites, driving cancer metastasis. A potential therapeutic strategy involves targeting these particles with an antibody drug that blocks E-selectin activity.
A team of researchers at Georgetown University's Lombardi Comprehensive Cancer Center has discovered a key role for glucose in regulating DNA synthesis and cancer cell response to chemotherapy. By targeting this pathway, the researchers hope to develop new treatments that make lung cancer more responsive to radiotherapy and chemotherapy.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
Researchers from Universitat de Barcelona and Universitat Internacional de Catalunya discuss the non-receptor protein tyrosine kinase Src as a good example of an oncogene. Targeting the Src N-terminal regulatory element (SNRE) has potential as oncotargets to inhibit Src activity only in cancer cells.
Researchers characterize a unique molecular mechanism in early stages of programmed cell death (apoptosis), a crucial process preventing cancer. By studying Bax protein interactions with mitochondrial lipids, they found that pore creation drives apoptosis initiation.
Cancer cells in brain tumors produce lipids at higher rates than surrounding healthy tissue, offering clues for treatment strategies. The study provides insights into the unique biochemical processes fueling cancer growth in the brain.
The MOSAIC project will use cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution. By analyzing thousands of patient samples, researchers aim to unlock novel cancer treatments and biomarkers through AI-powered analytics.
The nucleus is metabolically active and uses antioxidant enzymes to repair DNA damage. Cells relocate mitochondrial machinery to the nucleus in response to DNA damage, highlighting a paradigm shift in cellular biology.
Researchers developed a novel endoscopic imaging system with a bioinspired sensor that can detect multiple fluorescent probes, enabling more accurate fluorescence-guided cancer surgery. The system showed improved spatial resolution and sensitivity in detecting tumors, paving the way for the adoption of multi-tracer FGS.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers at the University of Gothenburg have developed a method to kill glioblastoma brain tumours by blocking stress in cancer cells. The treatment, which involves inserting a specially developed molecule into cells, shows promising results with no side effects.
Researchers discovered that FDA-approved HDAC-inhibitors can impact energy metabolism in solid tumor cells, including glioblastoma. The combination of HDAC-inhibitors and imipridones may synergize to enhance killing of GBM cells by reversing cellular respiration.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.
Researchers created organoids from patient tissues to test chemotherapy drugs and identified genetic signatures that predict treatment response, offering high accuracy in personalized drug screening. This breakthrough may help select effective drugs for individual patients, reducing trial and error.
A new study has provided insight into the mysterious evolution of DNA rings in tumors, revealing that nearly one-third of all tumors have these genetic structures. The researchers used a technology to trace the path of DNA ring development in neuroblastoma cells, finding that large rings contain cancer genes spurring cell growth.
New Finnish studies show that short bouts of light or moderate exercise can increase the number of immune cells capable of destroying cancer cells in cancer patients. The exercises were enough as short as 10 minutes to boost the immune system, with a positive impact on quality of life and prognosis.
Researchers identified copper's role in inflammation and found that it can trigger the expression of genes involved in cancer progression. They also developed a drug prototype called Supformin that blocks copper chemistry, reducing inflammation and cell transformation in cancer cells.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.
A research team from the Medical University of South Carolina identified a protein called TACC3 that enables cancer cells to successfully divide despite an abnormality that should lead to their death. This discovery offers new hope for developing targeted therapies to selectively kill cancer cells while leaving normal cells intact.
Researchers propose a new theory on how cancer cells actively adapt to evade the immune system, losing and gaining tumor-associated antigens. This adaptation makes it difficult for immunotherapies to target cancer cells effectively, but may also create new vulnerabilities that can be therapeutically targeted.
Two contagious cancers, devil facial tumour 1 (DFT1) and 2 (DFT2), affecting Tasmanian devils have been tracked to understand their origins and evolution. Researchers found DFT2 is a faster-growing cancer with rapid mutations, posing a significant threat to the species.
Scientists have identified a new emergency brake mechanism that prevents bladder cells from becoming cancerous, even when cancer-promoting genes are active. This discovery could lead to new therapeutic targets for bladder cancer treatment.
Researchers at Indiana University School of Medicine have identified a new target for breast cancer treatment, the gene TONSL, which can make breast cells proliferate indefinitely. The study found that TONSL is amplified in about 20% of breast cancers and more than 30% of metastatic breast cancers.
Acute myeloid leukemia is a cancer that affects blood cells and can lead to infection, anemia, and easy bleeding. The Georgia Cancer Center has received a $2.3 million grant to study how cancer cells resist treatment and propose new options to improve patient survival.
Research discovers how cancer cells evade immune system detection and metastasize in the body. Pre-metastatic cells and exhausted CD8+ cells are identified as key players in this process. The study explores ways to target these pathways and activate immune responses to block metastasis.
A team of scientists created a new, fast, and precise method for analyzing cells in tissue samples from cancer patients without the need for a trained pathologist. The method uses artificial intelligence to evaluate data produced by a technique called real-time deformability cytometry.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
Cancer-associated fibroblasts (CAFs) are a type of cell that plays a crucial role in the tumor microenvironment. The authors suggest that understanding CAFs is essential for developing effective cancer therapies. Research targeting CAFs has shown promise, but challenges remain due to their complex nature.
Researchers from Tokyo University of Science reveal the crystal structure of centromere-associated protein E (CENP-E), a promising target for inhibitor therapy. The discovery is expected to facilitate the development of anticancer drugs with fewer adverse effects on patients.
Researchers used microfluidic devices to track what happens to cancer cells as they migrate and take root in the brain. They found that Dkk-1 triggers cancer cell migration, and reducing its levels near tumor cells may disrupt crosstalk between brain niche cells and cancer cells.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
Scientists have engineered a unique strain of probiotic bacteria to over-express a metal transporter that binds and concentrates copper, facilitating the delivery of radionuclide therapy to cancer cells. This approach targets tumors without relying on specific receptors, making it potentially effective against treatment-resistant cancers.
Researchers discovered that cancer cells' glycocalyx thickness affects immune cell evasion and engineered immune cells work better with thinner barriers. They also developed special enzymes to overcome the barrier, potentially improving immunotherapies.
Researchers from Université Libre de Bruxelles discovered a protein named RHOJ that controls resistance to chemotherapy in cancer cells. By silencing RHOJ, cancer cells become sensitive to chemotherapy, paving the way for novel therapeutic strategies.
Researchers found that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes, potentially boosting efficacy against solid tumors. The study suggests leaving lymph nodes intact until after immunotherapy could improve treatment outcomes for patients with head and neck cancers.
Researchers created a three-dimensional structure that mimics bone and houses osteosarcoma cells beside immune cells, finding increased inflammation reduces chemotherapy effectiveness. The study highlights the importance of the tumor microenvironment in disease progression and treatment.
Researchers have discovered how TKI cancer drugs cause inflammation, linking it to mitochondrial dysfunction and the NLRP3 inflammasome. The study found that all tested TKIs share a common off-target activity against mitochondrial SFKs.
Scientists from the University of North Carolina at Charlotte review nucleolar DNA damage response pathways to combat cancer. By attacking these mechanisms, researchers aim to disrupt cancer's reproduction and growth.
Scientists discovered a new type of DNA repair mechanism that cancer cells use to recover from next-generation cancer radiation therapy. DNA polymerase θ (POLQ) is an important factor in repairing complex DNA double-strand breaks, and inhibiting POLQ may augment the efficacy of heavy ion radiation therapy.